Ionis Pharmaceuticals, Inc. (IONS)
42.93
-0.98
(-2.23%)
USD |
NASDAQ |
Oct 23, 16:00
42.91
-0.02
(-0.05%)
After-Hours: 20:00
Ionis Pharmaceuticals Enterprise Value : 7.245B for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 7.245B |
| October 22, 2026 | 7.408B |
| October 21, 2026 | 7.467B |
| October 20, 2026 | 7.654B |
| October 19, 2026 | 7.485B |
| October 16, 2026 | 7.247B |
| October 15, 2026 | 7.442B |
| October 14, 2026 | 7.207B |
| October 13, 2026 | 7.154B |
| October 12, 2026 | 7.368B |
| October 09, 2026 | 7.634B |
| October 08, 2026 | 7.307B |
| October 07, 2026 | 7.449B |
| October 06, 2026 | 7.422B |
| October 05, 2026 | 7.340B |
| October 02, 2026 | 7.346B |
| October 01, 2026 | 7.422B |
| September 30, 2026 | 7.530B |
| September 29, 2026 | 7.736B |
| September 28, 2026 | 7.683B |
| September 25, 2026 | 7.505B |
| September 24, 2026 | 7.391B |
| September 23, 2026 | 7.411B |
| September 22, 2026 | 7.712B |
| September 21, 2026 | 7.572B |
| Date | Value |
|---|---|
| September 18, 2026 | 7.495B |
| September 17, 2026 | 7.878B |
| September 16, 2026 | 7.562B |
| September 15, 2026 | 7.961B |
| September 14, 2026 | 8.655B |
| September 11, 2026 | 9.114B |
| September 10, 2026 | 9.352B |
| September 09, 2026 | 9.413B |
| September 08, 2026 | 9.528B |
| September 04, 2026 | 9.756B |
| September 03, 2026 | 9.763B |
| September 02, 2026 | 10.29B |
| September 01, 2026 | 10.05B |
| August 31, 2026 | 10.13B |
| August 28, 2026 | 10.25B |
| August 27, 2026 | 10.48B |
| August 26, 2026 | 10.63B |
| August 25, 2026 | 10.66B |
| August 24, 2026 | 10.41B |
| August 21, 2026 | 10.03B |
| August 20, 2026 | 9.867B |
| August 19, 2026 | 10.21B |
| August 18, 2026 | 10.01B |
| August 17, 2026 | 9.846B |
| August 14, 2026 | 9.615B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Alnylam Pharmaceuticals, Inc. | 29.64B |
| Biogen, Inc. | 44.10B |
| BridgeBio Pharma, Inc. | 16.08B |
| Vertex Pharmaceuticals, Inc. | 126.85B |
| Amgen, Inc. | 280.78B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -114.65M |
| Revenue (Quarterly) | 267.95M |
| Total Expenses (Quarterly) | 382.60M |
| EPS Diluted (Quarterly) | -0.6931 |
| Gross Profit Margin (Quarterly) | 96.13% |
| Profit Margin (Quarterly) | -42.79% |
| Earnings Yield | -8.09% |
| Normalized Earnings Yield | -8.526 |